Genetic Therapy for Pancreatic Cancer: Is it the Future?
Journal Title: Pancreas – Open Journal - Year 2018, Vol 2, Issue 1
Abstract
Although surgery is still the only curative therapy for pancreatic cancer, oncological therapies have started to be more and more promising. We firstly have to consider two important points. The first one is that surgery for pancreatic cancer is complex and risky: perioperative mortality is 4-18% and major complications occur in more than 40% of cases.1 Moreover, only 15-20% of patients have a resectable tumour at the first diagnosis.2 Furthermore, disease’s recurrence following operation is very high because of local invasion and micrometastases at the time of surgery.3 The second point is that the first chemotherapies for pancreatic cancer (5-fluoro-uracile, and the actually used, gemcitabine) are not specific for pancreatic tumours and have been provided only a little impact on overall survive.
Authors and Affiliations
Lorenzo Dioscoridi
Keywords
Related Articles
- EP ID EP556708
- DOI 10.17140/POJ-2-e005
- Views 167
- Downloads 0
Nutritional Support of Patients With the Abdominal Compartment Syndrome During Severe Acute Pancreatitis
There is growing evidence in the literature that development of Abdominal Compartment Syndrome (ACS) in patients with Severe Acute Pancreatitis (SAP) has a strong impact on the course of disease. Incidence of ACS in pati...
ADAM10 Proteases and Pancreatic Cancer
Pancreatic ductal adenocarcinoma (PDAC) is the 4th leading cause of cancer-related deaths in the United States and is expected to rise to the second rank by 2020.1 The survival rate of PDAC is estimated at less than 5% a...
Delayed Onset Post-ERCP Pancreatitis (DOPE-P)
Post Endoscopic retrograde cholangiopancreatography (ERCP) Pancreatitis (PEP) is defined as new onset or worsening of pain abdomen after ERCP with an elevation of pancreatic enzymes (amylase/lipase) more than 3 times upp...
Epithelial-To-Mesenchymal Transition in Pancreatic Ductal Adenocarcinoma: Fiction or Fact?
Pancreatic Ductal Adenocarcinoma (PDAC) is one of the most aggressive and lethal tumors, representing the fourth most common cause of cancer death in the Western world, with an estimated incidence of more than 40,000 cas...
Epigenetic Alterations in Pancreatic Cancer
Pancreatic cancer is the fourth leading cause of cancer death and is predicted to be the second leading cause in a decade in the US. Despite more than 50 years of research and therapeutic development, pancreatic cancer s...